




CARING FOR CHALLENGING CLOSURES WHEN PATIENTS NEED IT MOST



EPIFIX

Protective Barrier

- Protects the wound bed to aid in the development of granulation tissue

Provides a Human Biocompatible Extracellular Matrix (ECM)

- **Structural components:**
Collagen I, III, IV; elastin
- **Cell-binding domains:**
Fibronectin, collagen V, VII
- **ECM-binding domains:**
Proteoglycans, laminin

Retains Regulatory Proteins

- 300+ Regulatory Proteins¹⁻³



- Dehydrated amnion/chorion membrane sheet allograft

- EpiFix[®] is SMR²T_™ Technology

Selective Membrane of Reparative and Reconstructive Tissue



- Uses Purion[®] patented processing



EpiFix is a dehydrated human amnion/chorion membrane allograft. EpiFix sheets provide a semi-permeable protective barrier that supports the healing cascade and protects the wound bed to aid in the development of granulation tissue in acute and chronic closures. EpiFix provides a biocompatible human extracellular matrix and retains 300+ regulatory proteins.¹⁻³

Clinical Use Examples

- Comorbid patients with complex defects or delayed healing
- Diabetic foot ulcers (DFUs)
- Venous leg ulcers (VLUs)
- Debridements
- Decubitus ulcers

Product Advantages

- Most level I evidence in placental-based allografts: 6 EpiFix RCTs
- SMR²T Technology and patented Purion processing
- Terminally sterilized for additional level of safety
- Easy to apply
- Room temperature storage
- 5-year shelf life
- Compatible with negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBO)

Patient Insurance Verification Team:
855.882.8480



Patents and patents pending see: www.mimedx.com/patents. EpiFix, Purion, SMR²T, and MiMedx are trademarks of MiMedx Group, Inc. ©2020 MiMedx Group, Inc. All Rights Reserved. www.mimedx.com EP578.001

Published Studies	N	Outcomes Observed in Studies
DFU RCT: ^{4,5} EpiFix vs. Apligraf® vs. SOC	EpiFix: 32 Apligraf: 33 SOC: 35	Complete wound closure: 85% at 4 weeks (EpiFix vs. Apligraf $p=0.001$; EpiFix vs. SOC $p=0.001$) 95% at 6 weeks (EpiFix vs. Apligraf $p=0.0006$; EpiFix vs. SOC $p=0.0001$) 97% at 12 weeks (EpiFix vs. Apligraf $p=0.0001$; EpiFix vs. SOC $p=0.0001$)
VLU Multicenter RCT: ^{6,7} EpiFix vs. SOC	EpiFix: 52 SOC: 57	Complete wound closure (Per Protocol): 60% at 12 weeks ($p=0.0128$) 71% at 16 weeks ($p=0.0065$)

HOPD & WCC* Ordering Information

Item #	Size & Description
GS-5180	18 mm disk
GS-5220	2 cm x 2 cm sheet
GS-5230	2 cm x 3 cm sheet
GS-5240	2 cm x 4 cm sheet
GS-5340	3 cm x 4 cm sheet
GS-5440	4 cm x 4 cm sheet
GS-5560	5 cm x 6 cm sheet
GS-5770	7 cm x 7 cm sheet



Item #	Size & Description
ES-2300	2 cm x 3 cm mesh sheet
ES-3300	3.5 cm x 3.5 cm mesh sheet
ES-4400	4 cm x 4.5 cm mesh sheet
ES-5500	5 cm x 5.5 cm mesh sheet



*Q Code: 4186

Apligraf is a registered trademark of Organogenesis.



REFERENCES: 1. Koob, et al. J Biomed Mater Res B Appl Biomater. 2014 Aug;102(6):1353-62. 2. Lei, et al. Adv Wound Care. 2017 Feb 1;6(2):43-53. 3. MM-RD-00086, Proteome Characterization of Purion Processed Dehydrated Human Amnion Chorion Membrane (dHACM) and Purion Plus Processed Dehydrated Human Umbilical Cord (dHUC) Allografts. 4. Zelen, et al. Int Wound J. 2015 Dec;12(6):724-32. 5. Zelen, et al. Int Wound J. 2016 Apr;13(2):272-82. 6. Bianchi, et al. Int Wound J 2018 Feb;15(1):114-22. 7. Bianchi, et al. Int Wound J. 2019 Jun;16(3):761-67.

866.477.4219 • customerservice@mimedx.com